反応式
[CH3:1][O:2][C:3]1[CH:8]=[C:7]([CH3:9])[C:6]([S:10]([N:13]([CH2:15][C:16]2[O:20][C:19]([C:21]([O:23]C)=O)=[N:18][N:17]=2)[CH3:14])(=[O:12])=[O:11])=[C:5]([CH3:25])[CH:4]=1.[CH3:26][N:27]([CH3:37])[CH2:28][CH2:29][CH2:30][N:31]1[CH2:36][CH2:35][NH:34][CH2:33][CH2:32]1.C[Al](C)C>ClCCCl>[NH3:13].[CH3:37][N:27]([CH3:26])[CH2:28][CH2:29][CH2:30][N:31]1[CH2:32][CH2:33][N:34]([C:21]([C:19]2[O:20][C:16]([CH2:15][N:13]([CH3:14])[S:10]([C:6]3[C:7]([CH3:9])=[CH:8][C:3]([O:2][CH3:1])=[CH:4][C:5]=3[CH3:25])(=[O:12])=[O:11])=[N:17][N:18]=2)=[O:23])[CH2:35][CH2:36]1参加物
6
反応物 3
生成物 2
試薬・触媒・溶媒 1
実験手順
The title compound was prepared according to general procedure AT using methyl 5-({[(4-methoxy-2,6-dimethylphenyl)sulfonyl](methyl)amino}methyl)-1,3,4-oxadiazole-2-carboxylate (30 mg, 0.08 mmol), N,N-dimethyl-3-(piperazin-1-yl)propan-1-amine (27 mg, 0.16 mmol) and trimethylaluminium (2 M in toluene, 0.08 mL) in DCE (5 mL). The crude product was purified using FCC, eluting with 95:4.5:0.5 DCM:MeOH:NH3, to afford the title compound.
後処理
- customThe title compound was prepared
- customThe crude product was purified
- washeluting with 95:4.5:0.5 DCM
出典と根拠
- ORDレコード
- ord-f7b15319d22847419bcc366178068416
- 出典データセット
- uspto-grants-2014_01
- 特許番号
- US08623859B2
関連ノート
読み込み中…